# neoCARHP (NCT04858529)

> Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

No report yet. It can be ordered.

- Drugs tested: THP
- Indication: HER2-positive breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04858529
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Guangdong Provincial People's Hospital
- Conditions: Neoadjuvant Therapies for HER2+ Breast Cancer
- Interventions: investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP); investigator-selected taxane/trastuzumab/pertuzumab (THP)
- Enrollment: 774
- Primary outcome: pathological complete response(ypT0/is,ypN0, pCR)

## Questions raised in the commentary

_Automated from the 39 newest of 47 indexed sources (May 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether carboplatin can be omitted routinely or should be reserved for selected patients
- Whether carboplatin omission affects event-free or recurrence outcomes
- How far neoadjuvant chemotherapy can be de-escalated, including treatment duration

## Indexed commentary on neoCARHP so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 37
- YouTube: 5
- Podcasts: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=neocarhp-nct04858529

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04858529", "email": "<work email>"}; the inbox owner confirms by the emailed link.